{
    "organizations": [],
    "uuid": "8aa294204057de67cb1ff24d1b446bd7f30367ee",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-syndax-pharmaceuticals-reports-qtr/brief-syndax-pharmaceuticals-reports-qtrly-loss-per-share-0-80-idUSFWN1QN0QX",
    "ord_in_thread": 0,
    "title": "BRIEF-Syndax Pharmaceuticals Reports Qtrly Loss Per Share $0.80",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) - Syndax Pharmaceuticals Inc:\n* SYNDAX PHARMACEUTICALS - PHASE 2 ENCORE 601 PD-(L)1 REFRACTORY MELANOMA COHORT DATA AND MELANOMA REGISTRATION STRATEGY DISCLOSURE FORTHCOMING IN 2Q18\n* SYNDAX PHARMACEUTICALS INC - ENCORE 601 PD-(L)1 REFRACTORY NSCLC COHORT DATA EXPECTED 2Q18\n* SYNDAX PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.80\n* SYNDAX PHARMACEUTICALS INC - FOR Q1 RESEARCH AND DEVELOPMENT EXPENSES ARE EXPECTED TO BE $18 TO $22 MILLION\n* SYNDAX PHARMACEUTICALS INC - FOR FULL YEAR 2018 RESEARCH AND DEVELOPMENT EXPENSES ARE EXPECTED TO BE $67 TO $76 MILLION\n* SYNDAX PHARMACEUTICALS INC - TOTAL OPERATING EXPENSES ARE EXPECTED TO BE $22 TO $26 MILLION FOR Q1\n* SYNDAX PHARMACEUTICALS INC - TOTAL OPERATING EXPENSES ARE EXPECTED TO B $86 TO $96 MILLION FOR FULL YEAR 2018 Source text: ( bit.ly/2FWiCvz ) Further company coverage:\n ",
    "published": "2018-03-06T05:26:00.000+02:00",
    "crawled": "2018-03-06T22:30:58.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "syndax",
        "pharmaceutical",
        "inc",
        "syndax",
        "pharmaceutical",
        "phase",
        "encore",
        "l",
        "refractory",
        "melanoma",
        "cohort",
        "data",
        "melanoma",
        "registration",
        "strategy",
        "disclosure",
        "forthcoming",
        "2q18",
        "syndax",
        "pharmaceutical",
        "inc",
        "encore",
        "l",
        "refractory",
        "nsclc",
        "cohort",
        "data",
        "expected",
        "2q18",
        "syndax",
        "pharmaceutical",
        "inc",
        "qtrly",
        "loss",
        "per",
        "share",
        "syndax",
        "pharmaceutical",
        "inc",
        "q1",
        "research",
        "development",
        "expense",
        "expected",
        "million",
        "syndax",
        "pharmaceutical",
        "inc",
        "full",
        "year",
        "research",
        "development",
        "expense",
        "expected",
        "million",
        "syndax",
        "pharmaceutical",
        "inc",
        "total",
        "operating",
        "expense",
        "expected",
        "million",
        "q1",
        "syndax",
        "pharmaceutical",
        "inc",
        "total",
        "operating",
        "expense",
        "expected",
        "b",
        "million",
        "full",
        "year",
        "source",
        "text",
        "company",
        "coverage"
    ]
}